DNA Vaccine Innovation May Shift Treatment Paradigm for Patients Living with Recurrent Respiratory P скачать в хорошем качестве

DNA Vaccine Innovation May Shift Treatment Paradigm for Patients Living with Recurrent Respiratory P

Dr. Jeff Skolnik, Senior Vice President of Clinical Development at INOVIO Pharmaceuticals, discusses the current research and development of a DNA vaccine for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11. He also talks about other DNA-based medicines INOVIO is developing to treat cancers and infectious diseases. #INOVIOPharmaceuticals Jeffrey Skolnik, M.D. Senior Vice President, Clinical Development Dr. Skolnik leads INOVIO’s HPV and immuno-oncology DNA medicines teams. He is a key member of the leadership team overseeing global clinical assets for DNA medicines aimed to treat HPV-related disease and cancers. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He has held several leadership positions in Clinical Development and Medical Affairs for AstraZeneca and GSK, for both early and late-stage compounds. Dr. Skolnik received his M.D. degree with honors from New York University and received his pediatric training at Children’s Hospital, Boston and completed his hematology/oncology training at The Children’s Hospital of Philadelphia, where he continues on staff as an Attending Physician.